Comparison of the Effectiveness, Safety, and Satisfaction of Different Methods for Labor Induction

NCT ID: NCT06794385

Last Updated: 2025-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-22

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this interventional study is to compare the effectiveness, safety, and patient satisfaction associated with two commonly used methods of labor induction: low-dose oral misoprostol and the vaginal delivery system with dinoprostone.

The study aims to identify the most suitable induction method for specific subgroups of patients based on parity, body mass index (BMI), age, and cervical ripeness, as well as assess patient preferences for these induction methods.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Induction of Labour

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group undergoing labor induction with the dinoprostone vaginal delivery system

Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction. The medication will be inserted into the posterior fornix of the vagina, with the active substance being released over a 24-hour period. Maternal and fetal health will be monitored during their stay on the ward. Upon the onset of contractions or any signs of fetal distress, patients will be transferred to the delivery unit. If labor does not commence and the cervix remains unfavorable after 24 hours, a new vaginal delivery system will be inserted for an additional 24 hours. If no progress is observed within 48 hours of induction, a mechanical method for labor induction or cesarean delivery will be employed. After delivery, women will complete a questionnaire to assess their satisfaction with the childbirth experience.

Group Type ACTIVE_COMPARATOR

dinoprostone vaginal delivery system

Intervention Type DRUG

Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.

Group undergoing labor induction with the low dose peroral misoprostol

Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours until adequate uterine contractions and a favorable cervical condition are achieved. A maximum of 8 doses will be administered on the first day. If labor does not commence and the cervix remains unfavorable, a second induction cycle will be initiated the following day. If no progress occurrs after 48 hours from the induction, participants will undergo cesarean delivery, or alternative mechanical induction method will be used. Following delivery, participants will complete a questionnaire to assess their satisfaction with the childbirth experience.

Group Type ACTIVE_COMPARATOR

low dose peroral misoprostol

Intervention Type DRUG

Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dinoprostone vaginal delivery system

Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.

Intervention Type DRUG

low dose peroral misoprostol

Participants will be induced with a low-dose oral formulation of misoprostol, administered per protocol at 25 mcg every 2 hours

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gestational age between 37 0/7 and 42 0/7 weeks
* Singleton pregnancy
* Viable fetus in cephalic presentation
* Bishop score ≤ 6
* Maximum parity of three
* Reactive CTG at admission without pathological findings

Exclusion Criteria

* Age \< 18 years
* Gestational age \< 37 0/7 weeks
* Active labor
* Spontaneous rupture of membranes
* Non-reassuring CTG findings
* Suspected infection (e.g., fever \> 38°C, chorioamnionitis, or unexplained systemic infection)
* Contraindications to vaginal delivery or prostaglandin use
* Previous cesarean delivery or uterine surgery involving entry into the uterine cavity
* Significant fetal abnormalities
* Severe fetal growth restriction with an estimated fetal weight below the 3rd percentile
* Non-Slovenian-speaking participants
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Centre Ljubljana

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UMC Ljubljana

Ljubljana, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

POLONA PEČLIN

Role: CONTACT

0038615226162

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0120-403/2024-2711-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Different Medications to Induce Labor
NCT06259097 RECRUITING PHASE3
Prostin and Propess in Induction of Labor
NCT01635439 COMPLETED PHASE3
PROMMO Trial: Oral Misoprostol vs IV Oxytocin
NCT04478942 COMPLETED EARLY_PHASE1